公开(公告)号：US06638508B2

公开(公告)日：2003-10-28

申请号：US09100015

申请日：1998-06-19

申请人： Bilha Schechter ,  Ruth Arnon ,  Meir Wilchek

发明人： Bilha Schechter ,  Ruth Arnon ,  Meir Wilchek

IPC分类号： A61K39395

CPC分类号： B82Y5/00 ,  A61K47/557 ,  A61K47/6898 ,  A61K49/06 ,  A61K51/0497 ,  A61K2121/00 ,  A61K2123/00 ,  G01N33/531

摘要： The present invention relates to avidin-type molecules having 2,4,6-trinitrophenyl or lactosyl groups or being complexed with an antibody specific to the avidin-type molecule, which shifts the biodistribution pattern in tissues and organs to the liver, where these molecules accumulate at high levels over several days. These modified avidin-type molecules provide a means for delivery of diagnostic and therapeutic agents, including radionuclides to the liver and cells of the reticuloendothelial system (RES) for diagnosing and treating hepatic disorders and disorders of the RES.

摘要翻译： 本发明涉及具有2,4,6-三硝基苯基或乳糖基或与抗生物素蛋白型分子特异性抗体复合的抗生物素蛋白型分子，其将组织和器官中的生物分布模式转移到肝脏，其中这些分子 几天内积累在高水平。 这些修饰的抗生物素蛋白型分子提供了用于诊断和治疗RES的肝脏疾病和病症的诊断和治疗剂（包括放射性核素）到肝脏和网状内皮系统（RES）的细胞的递送手段。

公开(公告)号：US08883149B2

公开(公告)日：2014-11-11

申请号：US13063940

申请日：2009-08-19

申请人： Michael Sela ,  Yosef Yarden ,  Bilha Schechter ,  Tsipi Ben-Kasus

发明人： Michael Sela ,  Yosef Yarden ,  Bilha Schechter ,  Tsipi Ben-Kasus

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/32 ,  G01N33/566 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/32 ,  C07K2317/565

摘要： A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.

摘要翻译： 提供了鉴定具有组合改善的抗肿瘤活性的抗体组合的方法。 该方法包括：（a）鉴定抗ErbB-2抗体的结合表位; 和（b）选择表现出与ErbB-2上不同表位结合的抗ErbB-2抗体的至少两种抗体的组合，至少一种不同表位位于ErbB-2的二聚位点， 抗体与组合的改善的抗肿瘤活性的组合。 还提供了根据本发明揭示的新型抗体组合。

公开(公告)号：US06694171B1

公开(公告)日：2004-02-17

申请号：US09445977

申请日：2000-03-06

申请人： Amos Breskin ,  Rachel Chechik ,  Zvi Paltiel ,  Bilha Schechter ,  Abraham Warshawsky ,  Abraham Shanzer ,  Michal Neeman

发明人： Amos Breskin ,  Rachel Chechik ,  Zvi Paltiel ,  Bilha Schechter ,  Abraham Warshawsky ,  Abraham Shanzer ,  Michal Neeman

IPC分类号： A61B500

CPC分类号： A61K49/04

摘要： A delivery system and method for targeting a contrast agent to tissues and organs for improved diagnosis of tumors and for prognosis and follow-up of cancer therapy by X-ray imaging. The delivery system includes a conjugate or complex of a macromolecular carrier and a contrast agent selected from the group consisting of: (a) a compound having a heavy element with an atomic number in the range of 75 to 92, and (b) a compound having an element with a property of an abrupt change in its X-ray attenuation coefficient within the energy range used for radiography, said macromolecular carrier of said conjugate or complex being optionally linked to a specific tissue marker molecule.

摘要翻译： 用于将造影剂靶向组织和器官的递送系统和方法，用于改善肿瘤的诊断以及通过X射线成像进行癌症治疗的预后和随访。 递送系统包括大分子载体和造影剂的共轭物或复合物，其选自：（a）原子序数在75至92范围内的重元素的化合物，和（b）化合物 具有在用于放射照相的能量范围内其X射线衰减系数突然变化的性质的元件，所述缀合物或复合物的所述大分子载体任选地连接到特定的组织标记分子。

公开(公告)号：US09040047B2

公开(公告)日：2015-05-26

申请号：US14118243

申请日：2012-05-16

申请人： Michael Sela ,  Yosef Yarden ,  Bilha Schechter ,  Ruth Maron

发明人： Michael Sela ,  Yosef Yarden ,  Bilha Schechter ,  Ruth Maron

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/32 ,  A61N5/10 ,  A61K39/00

CPC分类号： A61K39/39558 ,  A61K2039/505 ,  A61K2039/507 ,  A61N5/10 ,  C07K16/2863 ,  C07K16/32

摘要： An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262); and (ii) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115), anti ErbB-2 L26 (CNCM Deposit Number I-4113) or anti ErbB-2 N12 (CNCM Deposit Number I-4112), or (iii) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 (CNCM Deposit Number I-4261); and (iv) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115). Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.

摘要翻译： 提供制造品。 制品包括被鉴定用于治疗癌症的包装材料，包装：（i）包含抗EGFR 565（CNCM保藏号I-4262）的CDR序列的抗EGFR抗体; 和（ii）抗ErbB-2抗体，其包含抗ErbB-2 L431（CNCM保藏号I-4115），抗ErbB-2 L26（CNCM保藏号I-4113）或抗ErbB-2 N12（ CNCM保藏号I-4112），或（iii）包含抗EGFR 111（CNCM存放号I-4261）的CDR序列的抗EGFR抗体; 和（iv）包含抗ErbB-2 L431（CNCM保藏号I-4115）的CDR序列的抗ErbB-2抗体。 还提供了药物组合物和使用上述抗体以及用于治疗癌症的其它抗体组合的方法。

公开(公告)号：US20110171206A1

公开(公告)日：2011-07-14

申请号：US13063940

申请日：2009-08-19

申请人： Michael Sela ,  Yosef Yarden ,  Bilha Schechter ,  Tsipi Ben-Kasus

发明人： Michael Sela ,  Yosef Yarden ,  Bilha Schechter ,  Tsipi Ben-Kasus

IPC分类号： A61K39/395 ,  G01N33/566 ,  A61P35/00

CPC分类号： A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/32 ,  C07K2317/565

摘要： A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.

摘要翻译： 提供了鉴定具有组合改善的抗肿瘤活性的抗体组合的方法。 该方法包括：（a）鉴定抗ErbB-2抗体的结合表位; 和（b）选择表现出与ErbB-2上不同表位结合的抗ErbB-2抗体的至少两种抗体的组合，至少一种不同表位位于ErbB-2的二聚位点， 抗体与组合的改善的抗肿瘤活性的组合。 还提供了根据本发明揭示的新型抗体组合。